Compare AXTA & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTA | KRYS |
|---|---|---|
| Founded | 1910 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.3B |
| IPO Year | 2014 | 2017 |
| Metric | AXTA | KRYS |
|---|---|---|
| Price | $30.21 | $216.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $37.00 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 4.7M | 325.5K |
| Earning Date | 10-28-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.67 | ★ 275.72 |
| EPS | 2.09 | ★ 6.66 |
| Revenue | ★ $5,166,000,000.00 | $373,164,000.00 |
| Revenue This Year | N/A | $34.33 |
| Revenue Next Year | $2.24 | $48.04 |
| P/E Ratio | ★ $14.40 | $32.72 |
| Revenue Growth | N/A | ★ 54.51 |
| 52 Week Low | $26.28 | $122.80 |
| 52 Week High | $40.80 | $221.84 |
| Indicator | AXTA | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 70.43 |
| Support Level | $29.30 | $213.24 |
| Resistance Level | $30.57 | $221.84 |
| Average True Range (ATR) | 0.88 | 6.84 |
| MACD | 0.16 | 0.66 |
| Stochastic Oscillator | 86.33 | 78.79 |
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.